AB Science S.A. (0Q77.L)
EUR 0.87
(-6.75%)
EUR 0.87
(-6.75%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -9.28 Million EUR | 52.86% |
| 2022 | -13.4 Million EUR | -1.61% |
| 2021 | -13.31 Million EUR | 17.15% |
| 2020 | -14.4 Million EUR | 33.31% |
| 2019 | -20.65 Million EUR | 17.83% |
| 2018 | -28.27 Million EUR | 6.14% |
| 2017 | -27.96 Million EUR | -2.0% |
| 2016 | -29.59 Million EUR | -2.86% |
| 2015 | -25.57 Million EUR | -71.01% |
| 2014 | -14.92 Million EUR | -15.39% |
| 2013 | -13.44 Million EUR | -29.78% |
| 2012 | -10.16 Million EUR | -7.87% |
| 2011 | -9.18 Million EUR | -6.28% |
| 2010 | -8.87 Million EUR | -14.22% |
| 2009 | -7.77 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.64 Million EUR | 0.0% |
| 2023 Q3 | -1.99 Million EUR | 79.22% |
| 2023 Q4 | -2.13 Million EUR | -6.76% |
| 2023 FY | - EUR | 52.86% |
| 2023 Q1 | -3.86 Million EUR | 55.51% |
| 2023 Q2 | -9.61 Million EUR | -148.83% |
| 2022 Q3 | -3.15 Million EUR | 69.84% |
| 2022 Q2 | -10.46 Million EUR | -126.99% |
| 2022 Q1 | -4.6 Million EUR | 43.88% |
| 2022 FY | - EUR | -1.61% |
| 2022 Q4 | -8.68 Million EUR | -175.08% |
| 2021 Q2 | -7.73 Million EUR | -171.2% |
| 2021 Q1 | -2.85 Million EUR | 67.66% |
| 2021 FY | - EUR | 17.15% |
| 2021 Q4 | -8.21 Million EUR | -115.79% |
| 2021 Q3 | -3.8 Million EUR | 50.81% |
| 2020 Q2 | -8.09 Million EUR | -154.11% |
| 2020 Q3 | -3.78 Million EUR | 53.29% |
| 2020 FY | - EUR | 33.31% |
| 2020 Q1 | -3.18 Million EUR | 60.25% |
| 2020 Q4 | -8.81 Million EUR | -133.21% |
| 2019 Q2 | -12.5 Million EUR | -149.87% |
| 2019 FY | - EUR | 17.83% |
| 2019 Q1 | -5 Million EUR | 30.63% |
| 2019 Q4 | -8.01 Million EUR | -136.22% |
| 2019 Q3 | -3.39 Million EUR | 72.87% |
| 2018 Q2 | -6.92 Million EUR | 0.0% |
| 2018 Q1 | -6.92 Million EUR | 4.56% |
| 2018 FY | - EUR | 6.14% |
| 2018 Q4 | -7.21 Million EUR | 0.0% |
| 2018 Q3 | -7.21 Million EUR | -4.25% |
| 2017 FY | - EUR | -2.0% |
| 2017 Q4 | -7.25 Million EUR | 0.0% |
| 2017 Q1 | -6.73 Million EUR | 4.25% |
| 2017 Q2 | -6.73 Million EUR | 0.0% |
| 2017 Q3 | -7.25 Million EUR | -7.74% |
| 2016 Q4 | -7.03 Million EUR | -1.16% |
| 2016 Q3 | -6.94 Million EUR | 7.65% |
| 2016 Q1 | -7.52 Million EUR | -14.07% |
| 2016 FY | - EUR | -2.86% |
| 2016 Q2 | -7.52 Million EUR | 0.0% |
| 2015 FY | - EUR | -71.01% |
| 2015 Q2 | -6.18 Million EUR | 0.0% |
| 2015 Q4 | -6.59 Million EUR | 0.0% |
| 2015 Q3 | -6.59 Million EUR | -6.61% |
| 2015 Q1 | -6.18 Million EUR | -64.19% |
| 2014 Q4 | -3.76 Million EUR | 0.0% |
| 2014 FY | - EUR | -15.39% |
| 2014 Q1 | -3.27 Million EUR | 13.61% |
| 2014 Q2 | -3.27 Million EUR | 0.0% |
| 2014 Q3 | -3.76 Million EUR | -15.18% |
| 2013 Q2 | -2.78 Million EUR | 0.0% |
| 2013 Q3 | -3.73 Million EUR | -34.15% |
| 2013 Q4 | -3.78 Million EUR | -1.33% |
| 2013 FY | - EUR | -29.78% |
| 2013 Q1 | -2.78 Million EUR | 0.0% |
| 2012 FY | - EUR | -7.87% |
| 2011 FY | - EUR | -6.28% |
| 2010 FY | - EUR | -14.22% |
| 2009 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Boiron SA | 80.67 Million EUR | 111.504% |
| Laboratorios Farmaceuticos Rovi, S.A. | 238.01 Million EUR | 103.899% |
| Vetoquinol SA | 104.58 Million EUR | 108.874% |
| Valneva SE | -64.51 Million EUR | 85.615% |
| Nanobiotix S.A. | -34.01 Million EUR | 72.718% |
| PHAXIAM Therapeutics S.A. | -22.93 Million EUR | 59.525% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 67.266% |
| BioSenic S.A. | -6.79 Million EUR | -36.566% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 93.033% |
| Formycon AG | 81.05 Million EUR | 111.451% |